Arcadia Biosciences reports FY2025 net loss of $2.3M; Zola revenues up 17% YoY; business combination terminated

Arcadia Biosciences, Inc.

Q4 2025 revenue $901K (-26% YoY); full-year revenue $4.86M (-4%). Net loss per share $1.71 vs $5.17 in 2024.
Zola coconut water sales rose 17% to $701K in 2025; SG&A reduced 27% YoY.
Roosevelt Resources terminated proposed business combination; Arcadia exercises preferred options for $2.1M gross proceeds.
Cash and short-term investments totaled $4.56M at Dec 31, 2025, down from $4.24M cash alone a year earlier.
Net cash used in operations improved 49% to $4.74M in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Arcadia Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.

Period: the fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 26, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-126220

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.